With the advent of advanced technologies like machine learning, artificial intelligence, and Internet of things in Canada, the Canada telemedicine market is expected to grow from $4.86 Bn in 2022 to $18.53 Bn in 2030 with a CAGR of 18.2% for year 2022-2030. The market is segmented by products and services, end user, and by delivery mode.
Lung cancer is the fifth most common type of cancer affecting the Australian population, therefore the Australia lung cancer drugs market is projected to grow during the forecast period. The market is segmented by type, treatment, end user, route of administration, and distribution channel.
Australia Over The Counter (OTC) drugs market is projected to grow from $2.04 Bn in 2022 to $3.95 Bn in 2030 with a CAGR of 8.6% for the year 2022-2030. Major OTC innovation trends include treatment based, lifestyle based, format based and extended offering. The market is segmented by drug type and by distribution channel.
Australia Primary Hyperoxaluria (PH) market stood at around $2.1 Mn in 2022 and is projected to reach $8.8 Mn with a CAGR of 19% for the year 2022-2030. The market is segmented by type, diagnosis, drug, treatment and by distribution channel. Alnylam Pharmaceuticals and Dicerna Pharmaceuticals are some of the key players in the Australia PH market.
Australia Sickle Cell Disease market is expected to grow from $1.1 Mn in 2022 to $2.6 Mn in 2030 with a CAGR of 11% for the year 2022 to 2030. The market is segmented by treatment modality and by distribution channel. Novartis and AstraZeneca are some of the key players in the Australia sickle cell disease market.
Brazil telemedicine market is projected to grow from $1.52 Bn in 2022 to $6.19 Bn in 2030 with a CAGR of 19.2% for the year 2022-2030. Brazil is a country with unique opportunities for the growth of telemedicine and hence will augment the growth of the telemedicine market. Cisco and GE Healthcare are the key players in the market.
Canada dermatology market is projected to grow from $2.78 Bn in 2022 to $5.31 Bn in 2030 with a CAGR of 8.44% for the year 2022-2030. More Canadians investing in skincare solutions is driving the Canada dermatology market. Major dermatological disorders in Canada are alopecia and psoriasis.
The Canada pharmacy market is expected to witness growth from $83.08 Bn in 2022 to $141.69 Bn in 2030 with a CAGR of 6.9% for the year 2022-2030. Major market drivers include increasing health expenditure and a rise in per capita disposable income. The market is segmented by industry products and services and by pharmacy groups.
The China antiepileptics drugs market stood at around $0.82 Bn in 2022 and is projected to reach $1.32 Bn in 2030 with a CAGR of 2.3% for the year 2022-2030. Valproic acid and Lamotrigine are the top selling antiepileptic drugs in China. The market is segmented by generation and by distribution channel.
The China dermatology therapeutics market is projected to grow from $2.79 Bn in 2022 to $5.96 Bn in 2030 with a CAGR of 9.94% for the year 2022-2030. As China is one of the countries with a lot of focus on skin-related disorders and skincare routines, the market is projected to grow during the forecast period.
The increase in healthcare expenditure and the introduction of novel treatments for psoriasis in China are causing the China psoriasis market to grow during the forecast period. Major diseases in China include plaque psoriasis, nail psoriasis, and guttate psoriasis. The market is segmented by drug class, distribution channel, and route of administration.
The China telemedicine market is expected to witness growth from $4.88 Bn in 2022 to $20.59 Bn in 2030 with a CAGR of 19.7% for the year 2022-2030. China shows a lot of potential for the growth of telemedicine providers in the country. The market is segmented by products and services, type, specialty, and by delivery mode.